表紙
市場調查報告書

焦點市場分析:子宮內膜異位症

Market Spotlight: Endometriosis

出版商 Datamonitor Healthcare 商品編碼 573556
出版日期 內容資訊 英文 40 Pages
商品交期: 最快1-2個工作天內
價格
焦點市場分析:子宮內膜異位症 Market Spotlight: Endometriosis
出版日期: 2020年08月19日內容資訊: 英文 40 Pages
簡介

預計世界15-49歲女性人口的子宮內膜異位症患病率將從2017年的1.887億增加到2026年的1.991億。據估計,子宮內膜異位症會影響15至49歲育齡婦女中的十分之一。子宮內膜異位症領域批准的藥物有靶向促性腺激素釋放激素受體,孕激素受體,促卵泡激素和雄激素受體。大多數非處方藥都是通過皮下途徑給藥的,但也可以口服和肌內給藥。

本報告提供全球子宮內膜異位症的市場調查,彙整疾病的背景·概要,患病人數的10年預測,開發平台藥物及已上市藥物概要,臨床試驗狀況,授權·資產收購等的主要交易趨勢,專利資訊,主要藥物的收益預測等資料。

概要

要點

疾病的背景

治療

  • GnRH 類比
  • 黃體激素
  • 混合口服避孕藥
  • 非類固醇消炎劑 (NSAID)
  • Danocrine
  • 手術

流行病學

已上市藥物

開發平台藥物

近幾年的活動·分析師的見解

近幾年的活動

成功概率

母專利

商機

臨床試驗環境

  • 贊助商:各狀態
  • 贊助商:不同階段
  • 近幾年的活動

文獻

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0178894

This Market Spotlight report covers the Endometriosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2019, there were 191.0 million prevalent cases of endometriosis in women aged 15-49 years worldwide, and forecasts that number to increase to 201.8 million prevalent cases by 2028.

Endometriosis affects an estimated one in 10 women in the reproductive age group of 15-49 years. The approved drugs in the endometriosis space target the gonadotropin-releasing hormone receptor, progesterone receptor, follicle-stimulating hormone, and androgen receptors. The majority of marketed drugs are administered via the subcutaneous route, while oral and intramuscular formulations are also available.

The majority of industry-sponsored drugs in active clinical development for endometriosis are in Phase II, with two drugs in Phase III.

Therapies in development for endometriosis focus on targets such as the gonadotropin-releasing hormone receptor, progesterone receptor, luteinizing hormone receptor, androgen receptors, and follicle-stimulating hormone. The majority of pipeline drugs are administered via the oral route, with only one product being tested as a topical formulation.

Topline Phase III trial results for Trelstar is the only high-impact upcoming event in the endometriosis space. The overall likelihood of approval of a Phase I gynecology asset is 16%, and the average probability a drug advances from Phase III is 70%. Drugs, on average, take 11.8 years from Phase I to approval, compared to 13.0 years in the overall obstetrics/gynecology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for endometriosis have been in the early and mid-phases of development, with 73% of trials in Phase I-II, and only 27% in Phase III-IV.

The US has a substantial lead in the number of endometriosis clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.

Clinical trial activity in the endometriosis space is dominated by completed trials. Bayer has the highest number of completed clinical trials for endometriosis, with 38 trials.

Bayer leads industry sponsors with the highest overall number of clinical trials for endometriosis, followed by AbbVie and Takeda.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • GnRH analogs
  • Progestins
  • Combined oral contraceptives
  • Non-steroidal anti-inflammatory drugs
  • Danocrine
  • Surgery

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Relugolix for Endometriosis (June 23, 2020)
  • Relugolix for Endometriosis (April 22, 2020)
  • Relugolix for Endometriosis (October 31, 2019)
  • Proellex (Oral) for Endometriosis (June 25, 2019)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Myovant Licenses Ex-US Relugolix Rights To Gedeon Richter

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of endometriosis, 2019-28
  • Figure 2: Overview of pipeline drugs for endometriosis in the US
  • Figure 3: Pipeline drugs for endometriosis, by company
  • Figure 4: Pipeline drugs for endometriosis, by drug type
  • Figure 5: Pipeline drugs for endometriosis, by classification
  • Figure 6: Relugolix for Endometriosis (June 23, 2020): Phase III - SPIRIT 1
  • Figure 7: Relugolix for Endometriosis (April 22, 2020): Phase III - SPIRIT 2
  • Figure 8: Key upcoming events in endometriosis
  • Figure 9: Probability of success in the endometriosis pipeline
  • Figure 10: Clinical trials in endometriosis
  • Figure 11: Top 10 drugs for clinical trials in endometriosis
  • Figure 12: Top 10 companies for clinical trials in endometriosis
  • Figure 13: Trial locations in endometriosis
  • Figure 14: Endometriosis trials status
  • Figure 15: Endometriosis trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of endometriosis, 2019-28
  • Table 2: Marketed drugs for endometriosis
  • Table 3: Pipeline drugs for endometriosis in the US
  • Table 4: Relugolix for Endometriosis (June 23, 2020)
  • Table 5: Relugolix for Endometriosis (April 22, 2020)
  • Table 6: Relugolix for Endometriosis (October 31, 2019)
  • Table 7: Proellex (Oral) for Endometriosis (June 25, 2019)
  • Table 8: Historical global sales, by drug ($m), 2015-19
  • Table 9: Forecasted global sales, by drug ($m), 2020-24